Our preclinical drug compound, COTI-2, has a major mechanism of action in human cancer cells that is dependent on p53 gene mutation status. This is important as drug treatment for p53 mutations represents a novel therapy and would be a first in class treatment for the drug company bringing COTI-2 to market. Unlike nearly every other cancer treatment in existence today, COTI-2 is non-genotoxic. Conventional chemotherapy involves the killing of all growing and dividing cells in the body (cancer or otherwise), which often leads to significant toxic side effects in patients. By contrast, COTI-2 specifically targets and primarily destroys tumor cells.
Posted on: Wed, 17 Jul 2013 14:17:29 +0000
Trending Topics
Recently Viewed Topics
© 2015